San Antonio breast cancer conference brings the latest research work in the field of breast cancer. This is an annual event where breast cancer scientists all over the world come together to present the research findings. In one of the studies presented at the San Antonio breast cancer meeting it was shown that after surgery for early-stage breast cancer, women may be treated with tamoxifen for 5 years. After that point, therapy with Aromasin significantly improves survival, as per a new study.

The study presented finding shows that Aromasin, following tamoxifen reduces breast cancer recurrence "by about half," reported Dr. Terry Mamounas of the Aultman Health Foundation of Canton, Ohio.

The study randomly assigned 1,598 postmenopausal women with early-stage breast cancer to take exemestane or an inactive placebo, beginning after five years on tamoxifen.

Women taking exemestane were 50 percent less likely to see a recurrence of breast cancer. The drug was as well-tolerated, with adverse events approximately the same as with placebo. Fatigue, joint pain and bone pain were the most common complaints.


Posted by: Janet    Source

---